Market Access Vaccines, MSD, Lyon, France.
Center for Observational and Real-world Evidence, MSD, Madrid, Spain.
Expert Rev Vaccines. 2021 Jun;20(6):639-647. doi: 10.1080/14760584.2021.1905257. Epub 2021 Jul 21.
Disease prevention and improving vaccination coverage in Europe are key elements contributing to resilient health systems and ensuring better health outcomes for all. The aim of this study was to describe the immunization funding landscape across all European Union 28 countries (EU28).
Data collected in a targeted literature review supported descriptive analysis on the different indicators that were looked at: vaccines included in the EU28 national immunization programs (NIP), national immunization funding, immunization funding per capita (2015-2019) and percentage of health-care budget allocated to immunization.
Immunization funding represents a small proportion of total healthcare spend in Europe (median 0.3%). In the context of the current COVID-19 pandemic, demographic changes, and the potential introduction of new vaccines; the need for adequate financing of immunization programs will be important, to establish resilient immunization systems and provide sustainable protection of the population against vaccine-preventable diseases.
疾病预防和提高疫苗接种覆盖率是欧洲建立有韧性的卫生系统和确保全民更好健康结果的关键因素。本研究的目的是描述整个欧盟 28 国(EU28)的免疫接种资金状况。
在有针对性的文献综述中收集的数据支持了对以下不同指标的描述性分析:纳入欧盟 28 个国家免疫规划(NIP)的疫苗、国家免疫接种资金、人均免疫接种资金(2015-2019 年)以及用于免疫接种的卫生保健预算的百分比。
免疫接种资金在欧洲的总医疗保健支出中占很小的比例(中位数为 0.3%)。在当前 COVID-19 大流行、人口结构变化以及可能引入新疫苗的背景下,为免疫规划提供充足的资金将非常重要,这对于建立有韧性的免疫体系以及为人群提供可持续的疫苗可预防疾病保护至关重要。